Comparing the current results to its competitors, Intellia Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -46.23 %, despite the revenue increase by the most of its competitors of 12.43 %, recorded in the same quarter.
Intellia Therapeutics Inc , slower than the average decrease reported by the company's competitors of -15 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -15 %
Intellia Therapeutics Inc 's Comment on Competition and Industry Peers
Intellia Therapeutics, Inc. operates in a competitive environment marked by rapid technological advancements. The company competes with entities utilizing genome editing, gene therapy platforms, and traditional therapeutic approaches such as small molecules and antibodies. Competitors include large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies, and both public and private research organizations, many of which possess greater capital and resources. For its lonvo-z program targeting hereditary angioedema (HAE) treatment, Intellia faces competition from companies currently commercializing or developing products, including ADARx Therapeutics, Inc., Argo Biopharmaceutical Co., Ltd., BioCryst Pharmaceuticals Inc., CSL Limited, Gritgen Therapeutics Co., Ltd., Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Pharming Group N.V., Pharvaris N.V., and Takeda Pharmaceutical Company Limited.
March 20, 2025
In a landscape where innovative medical therapeutics often drive market excitement, Intellia Therapeutics, Inc. (NASDAQ: NTLA) is currently navigating both financial headwinds and potential legal challenges. Rosen Law Firm, a prominent global investor rights law firm, has recently issued a reminder to those who purchased Intellia securities between July 30, 2024, and January 8, 2025, regarding a critical deadline for securing legal counsel. Investors must take note of the April 14, 2024, deadline to act as lead plaintiffs in an impending securities class action.While the potential for litigation hangs in the air, the company s financial performance during the fourth quarter of 2024 reveals some troubling tre...
July 30, 2024
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a prominent player in the clinical-stage gene editing landscape, has recently made strides that promise to revolutionize treatment options for rare genetic disorders. The company, headquartered in Cambridge, Massachusetts, announced the authorization of its Clinical Trial Application (CTA) from the United Kingdom s Medicines and Healthcare products Regulatory Agency (MHRA) to embark on a Phase 1/2 clinical trial evaluating NTLA-3001. This investigational treatment aims specifically at lung disease associated with alpha-1 antitrypsin deficiency (AATD), a genetic condition that frequently results in severe lung dysfunction. Understanding Alpha-1 Antitrypsin Deficienc...
June 25, 2024
Pioneering Advancements: Intellia Demonstrates Positive Data for Redosing CRISPR Therapy and Long-Term Efficacy in Hereditary Angioedema CAMBRIDGE, Mass., June 25, 2024 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leader in clinical-stage gene editing aimed at revolutionizing medicine with CRISPR-based therapies, has reached a momentous milestone by presenting new data exhibiting the possibility of redosing with an investigational in vivo CRISPR/Cas9 genome editing therapy. This groundbreaking revelation was showcased at the Peripheral Nerve Society Annual Meeting held from June 22-25 in Montreal, Canada. The data was derived from the ongoing Phase 1 study of NTLA-2001, a single-dose intervention unde...
June 2, 2024
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneering clinical-stage genome editing company dedicated to transforming medicine through CRISPR-based therapies, has once again captivated the scientific community with its groundbreaking long-term data from the Phase 1 portion of an ongoing Phase 1/2 study of NTLA-2002. This investigational in vivo CRISPR-based gene editing therapy promises a single-dose solution for hereditary angioedema (HAE), a rare and often life-threatening genetic disorder characterized by severe swelling attacks.The company unveiled its remarkable findings during an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, held from May 31 to J...
Publicly Traded Peers of Intellia Therapeutics Inc
Vertex Pharmaceuticals Inc Share Performance
+19.73%
This Quarter
Vertex Pharmaceuticals Inc
Profile
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Portage Biotech Inc.'s business model involves the identification and development of innovative therapeutics and healthcare solutions, leveraging a unique portfolio of biotechnology companies and their technologies.
Prime Medicine Inc is a biotechnology company specializing in gene editing technologies and therapeutics. Their business model revolves around harnessing advanced CRISPR-based gene editing techniques to develop treatments for genetic diseases. By using innovative science and strategic partnerships, the company aims to bring transformative therapies to patients in need.
Pluri Inc's business model revolves around providing digital solutions and services to various clients. They leverage their expertise and technology to offer customized software development, IT consulting, and digital marketing services. With a focus on delivering tailored solutions, Pluri Inc aims to meet the specific needs and goals of their clients and support their growth in the digital landscape.
Omniab Inc is a technology company that operates on a B2B (business-to-business) model, offering a range of software solutions and services. The company focuses on providing customized software applications to help businesses streamline their operations, enhance productivity, and improve efficiency. Omniab Inc also offers consultation services to assist companies in optimizing their IT infrastructure.
Sources:
Intellia Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Intellia Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
